Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

2(40.0%)

Phase 2

2(40.0%)

N/A

1(20.0%)

5Total

Phase 1(2)

Phase 2(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07394452Phase 1Completed

Single Ascending Dose Study(SAD),Multiple Ascending Dose Study(MAD) , High-fat Diet Study (FE) of TJ0113 Capsules in Healthy Subjects

Role: lead

NCT07018245Phase 2Recruiting

Clinical Trial of TJ0113 Capsules in the Treatment of Patients With Depressive Disorder

Role: lead

NCT06596005Phase 2Completed

Efficacy and Safety of TJ0113 Capsule in Patients With Parkinson's Disease

Role: collaborator

NCT06832540Phase 1Completed

Mass Balance Study of [14C] TJ0113 in Healthy Chinese Subjects

Role: lead

NCT07012746Not ApplicableNot Yet Recruiting

A Clinical Trial of the Safety and Efficacy of TJ0113 Capsules in the Treatment of Patients With Age-related Hearing Loss

Role: collaborator

All 5 trials loaded